Interferon in the treatment of chronic hepatitis C: a drug caught between past and future

Bibliography

• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81
   PubMed Web of Science ®Google Scholar
• Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(Suppl):S30-4
   PubMedGoogle Scholar
• Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007;14:107-15
   PubMed Web of Science ®Google Scholar
• Simmonds P, Bukh J, Combet C, Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73
   PubMed Web of Science ®Google Scholar
• Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305
   PubMedGoogle Scholar
• Fattovich G, Giustina G, Degos F, Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72
   PubMed Web of Science ®Google Scholar
• Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-98
   PubMedGoogle Scholar
• John-Baptiste AA, Tomlinson G, Hsu PC, Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol 2009;104:2439-48
   PubMed Web of Science ®Google Scholar
• Omland LH, Krarup H, Jepsen P, Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010;53:36-42
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Mullen KD, Jones DB, Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
   PubMed Web of Science ®Google Scholar
• Mogensen KE, Lewerenz M, Reboul J, The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res 1999;19:1069-98
   PubMed Web of Science ®Google Scholar
• Bach EA, Aguet M, Schreiber RD. The IFNgamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-91
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Gallagher G, Baurin VV, IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-8
   PubMed Web of Science ®Google Scholar
• Doyle SE, Schreckhise H, Khuu-Duong K, Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906
   PubMed Web of Science ®Google Scholar
• Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 2009;35:82-7
   PubMed Web of Science ®Google Scholar
• Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-87
   PubMed Web of Science ®Google Scholar
• Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993;42:57-102
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83
   PubMed Web of Science ®Google Scholar
• Peters M. Actions of cytokines on the immune response and viral interactions: an overview. Hepatology 1996;23:909-16
   PubMed Web of Science ®Google Scholar
• Baron S, Tyring SK, Fleischmann WR Jr, The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375-83
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83
   PubMed Web of Science ®Google Scholar
• Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26(3 Suppl 1):83S-88S
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-332
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92
   PubMed Web of Science ®Google Scholar
• Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539-51
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of Pegylation on biological therapies. BioDrugs 2008;22:315-29
   PubMed Web of Science ®Google Scholar
• Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94
   PubMed Web of Science ®Google Scholar
• Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004;20:825-30
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, ; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55
   PubMed Web of Science ®Google Scholar
• Rumi MG, Aghemo A, Prati GM, Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15
   PubMed Web of Science ®Google Scholar
• Ascione A, De Luca M, Tartaglione MT, Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138(1):116-22
   PubMed Web of Science ®Google Scholar
• Awad T, Thorlund K, Hauser G, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51:1176-84
   PubMed Web of Science ®Google Scholar
• Rumi MG. Pegylated interferon alphaalpha2b versus pegylated interferon alpha2a for chronic hepatitis C: the unreached goal of superiority. J Hepatol 2009;51:1097-9
   PubMedGoogle Scholar
• Craxì A. PEG IFN alfa-2a vs. alfa-2b: and the winner is ...? J Hepatol 2010;52:133-5
   PubMed Web of Science ®Google Scholar
• Aghemo A, Colombo M. Peginterferon alfa-2B versus peginterferon alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal. Gastroenterology 2010;138:386-9
   PubMedGoogle Scholar
• Bronowicki JP, Ouzan D, Asselah T, Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131(4):1040-8
   PubMed Web of Science ®Google Scholar
• McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475-81
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47
   PubMed Web of Science ®Google Scholar
• Witthoeft T, Hueppe D, John C, Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat 2010;17:459-68
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Muir AJ, Sulkowski MS, Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9
   PubMed Web of Science ®Google Scholar
• McCarthy JJ, Li JH, Thompson A, Replicated association between an IL-28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-14
   PubMed Web of Science ®Google Scholar
• Mangia A, Thompson AJ, Santoro R, An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821-7
   PubMed Web of Science ®Google Scholar
• Bruno S, Shiffman ML, Roberts SK, Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51(2):388-97
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried MW, Shiffman ML, Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33
   PubMed Web of Science ®Google Scholar
• Mangia A, Santoro R, Minerva N, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17
   PubMed Web of Science ®Google Scholar
• Kamal SM, El Kamary SS, Shardell MD, Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007;46:1732-40
   PubMed Web of Science ®Google Scholar
• Davis GL, Wong JB, McHutchison JG, Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52
   PubMed Web of Science ®Google Scholar
• Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-94
   PubMed Web of Science ®Google Scholar
• Berg T, von Wagner M, Nasser S, Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97
   PubMed Web of Science ®Google Scholar
• Mac Nicholas R, Norris S. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV – the role of epoetin, G-CSF and novel agents. Aliment Pharmacol Ther 2010;31:929-37
   PubMed Web of Science ®Google Scholar
• Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-8
   PubMed Web of Science ®Google Scholar
• Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006;24:1067-77
   PubMed Web of Science ®Google Scholar
• Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64
   PubMed Web of Science ®Google Scholar
• Balan V, Nelson DR, Sulkowski MS, A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006;11:35-45
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Sulkowski MS, Lawitz EJ, ; ACHIEVE-1 Study Team. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010;139:1257-66
   PubMed Web of Science ®Google Scholar
• Nelson DR, Benhamou Y, Chuang WL, ; ACHIEVE-2/3 Study Team. Albinterferon alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology. 2010;139:1267-76
   PubMed Web of Science ®Google Scholar
• Human Genome Sciences announces preliminary feedback from FDA on Zalbin BLA for chronic hepatitis C [press release]. Rockville, MD: Human Genome Sciences, Inc.; 14 June 2010. Available from: http://www.hgsi.com/latest/human-genome-sciences-announces-preliminary-feedback-from-fda-on-zalbin-bla-for-chronic-hepati-7.html [ Last accessed 6 January 2011]
   Google Scholar
• Human Genome Sciences announces withdrawal of European Marketing Authorization Application for Jouferon® Zalbin™ for the treatment of chronic hepatitis C [press release]. Rockville, MD: Human Genome Sciences, Inc.; 19 April 2010. Available from: http://www.hgsi.com/latest/human-genome-sciences-announces-withdrawal-of-european-marketing-authorization-application-for-joulferon-zalbin-for-the-treatment-of-chronic-hepati-7.html [Last accessed 6 January 2011]
   Google Scholar
• Sheppard P, Kindsvogel W, Xu W, IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-8
   PubMed Web of Science ®Google Scholar
• Marcello T, Grakoui A, Barba-Spaeth G, Interferons alpha and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131:1887-98
   PubMed Web of Science ®Google Scholar
• Doyle SE, Schreckhise H, Khuu-Duong K, Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906
   PubMed Web of Science ®Google Scholar
• Miller DM, Klucher KM, Freeman JA, Interferon lambda as a potential new therapeutic for hepatitis C. Ann NY Acad Sci 2009;1182:80-7
   PubMed Web of Science ®Google Scholar
• Muir AJ, Shiffman ML, Zaman A, Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52:822-32
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, ; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL-28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45
   PubMed Web of Science ®Google Scholar
• Adolf GR. Human interferon omega – a review. Mult Scler 1995;1(Suppl 1):S44-7
   PubMedGoogle Scholar
• Okuse C, Rinaudo JA, Farrar K, Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy. Antiviral Res 2005;65:23-34
   PubMed Web of Science ®Google Scholar
• Buckwold VE, Wei J, Huang Z, Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. Antiviral Res 2007;73:118-25
   PubMed Web of Science ®Google Scholar
• Novozhenov V, Zakharova N, Vinogradova E, Phase II study of omega interferon alone or in combination with tribavirin in subjects with chronic hepatitis C genotype-1 infection. J Hepatol 2007;46(Suppl 1):S8
   Google Scholar
• Rohloff CM, Alessi TR, Yang B, DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months. J Diabetes Sci Technol 2008;2:461-7
   PubMedGoogle Scholar
• Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment. Bethesda, MD, clinicaltrials.gov, 2007, Available from: http://www.clinicaltrials.gov/ct2/show/NCT00519792?term=Hepatitis&recr=Open&rank=117. [Last accessed 6 January 2011]
   Google Scholar
• Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996;16:489-99
   PubMed Web of Science ®Google Scholar
• Bacon BR, Shiffman ML, Mendes F, Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009;49:1838-46
   PubMed Web of Science ®Google Scholar
• Blatt LM, Cheung E, Radhakrisma R, A phase 1, single-blind, dose-escalating study of the safety and pharmacokinetics of a single injection of pegylated interferon alfacon-1 in healthy volunteers [abstract]. Gastroenterology 2005;128:S713
   Google Scholar
• Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98
   PubMed Web of Science ®Google Scholar
• Zhou Y, Muh U, Bartel D, In vitro characterizarion of Telaprevir (VX-950) NS3 Protease variants [abstract 89]. Hepatology 2006;44(4 Suppl 1):S221A
   Google Scholar
• Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 2006;69:129-41
   PubMed Web of Science ®Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77
   PubMed Web of Science ®Google Scholar
• Susser S, Welsch C, Wang Y, Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009;50:1709-18
   PubMed Web of Science ®Google Scholar
• Hezode C, Forestier N, Dusheiko G, ; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ, ; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, ; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16
   PubMed Web of Science ®Google Scholar
• Forns X, Marcellin P, Ferenci P, On-treatment response-guided therapy with Telaprevir q8h or q12h combined with Peginterferon alfa-2a or peginterferon alfa-2b and Ribavirin in treatment-naive genotype 1 hepatitis C (Study C208) [abstract 56]. J Hepatol 2010;52(1 Suppl 1):S26
   Google Scholar
• Gane EJ, Roberts SK, Stedman CA, Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Asselah T, Angus PW, Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. AASLD 2010 Annual Meeting. Hepatology 2010;52(4 Suppl 1): abstract LB-7
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Hirakawa M, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010;52:421-9
   PubMed Web of Science ®Google Scholar
• Ferenci P, Brunner H, Laferl H, ; Austrian Hepatitis Study Group. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008;47:1816-23
   PubMed Web of Science ®Google Scholar
• Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009;13:403-17
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN alpha2a in Chronic Hepatitis C Genotype 2 and 3 naive Patients. Bethesda, MD, clinicaltrials.gov, 2010. Available from: http://clinicaltrials.gov/show/NCT01215643. [Last accessed 6 January 2011]
   Google Scholar
• Silybin drug information. U.S. National Library of Medicine, Bethesda, MD, 2011. Available from: http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&APPLICATION_NAME=drugportal&actionHandle=default&nextPage=jsp/drugportal/ResultScreen.jsp&TXTSUPERLISTID=0022888706&QV1=SILYBIN [Last accessed 5 January 2011]
   Google Scholar
• Ferenci P, Scherzer TM, Kerschner H, Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008;135:1561-7
   PubMed Web of Science ®Google Scholar
• Ferenci P, Munda P. Intravenous Silibinin in combination with Peg-interferon and Ribavirin in nonresponders (NRSily). Clinical Trial NCT00684268. Bethesda, MD, clinicaltrials.gov, 2008. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00684268?term=NCT00684268&rank=1 [Last accessed 6 January 2011]
   Google Scholar
• Scherze T, Staube ER, Maieron A, Undetectable HCV RNA after Silibinin iv treatment is associated with high on treatment response rates in HCV nullresponders. AASLD 2010 Annual Meeting [abstract 835]. Hepatology 2010;52(4 Suppl l):723A
   Web of Science ®Google Scholar
• Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009;11:456-62
   PubMed Web of Science ®Google Scholar